Kevin Mccaffery from brings to light a very interesting topic on mergers and acquisitions (M&A) in the pharmaceutical industry. In the article, Mccaffery reviews the big slump in M&A activity with 2012 being the worst in recent history. While it looked like the trend would continue, things changed dramatically in 2013 with increases in every category. The biggest change came in deal value with an increase by 45 billion which is a 45.8% increase from 2012. To read the full article click here.